Pearls From the Pros on IBD Management: JAK Inhibition in IBD Practice With Drs. David Rubin and Millie Long
In this podcast, expert clinicians discuss the latest updates on JAK inhibition in IBD management.
6 Jan 202221min
Pearls From the Pros on IBD Management: Anti-IL-12/23 in IBD Practice With Drs. David Rubin and Bruce Sands
In this podcast, expert clinicians discuss the latest updates on anti-IL-12/23 therapy in IBD management.
6 Jan 202216min
Pearls From the Pros on IBD Management: Anti-TNF Therapy in IBD Practice With Drs. David Rubin and Stephen Hanauer
In this podcast, expert clinicians discuss the latest updates on anti-TNF therapy in IBD management.
6 Jan 202222min
Immunogenicity of Current IBD Biologics With Drs. Edward Loftus and Marla Dubinsky
In this podcast, expert clinicians compare the immunogenicity of available biologic therapies and explore options for managing patients who develop anti-drug antibodies.
18 Aug 202113min
Extraintestinal Manifestations of IBD With Drs. Edward Loftus and Miguel Regueiro
In this podcast, expert clinicians review the variety of extraintestinal manifestations seen in patients with IBD, discussing strategies for assessment and management.
18 Aug 202110min
Biologics for IBD – Monotherapy Versus Combination Approaches With Drs. Edward Loftus and Marla Dubinsky
In this podcast, experts review appropriate applications of monotherapy and combination therapy and how to position particular therapies based on disease and patient characteristics.
18 Aug 202114min
New Insights on Treat to Target in Moderate to Severe IBD With Drs. Edward Loftus and Miguel Regueiro
In this podcast, expert clinicians will discuss the shift from symptom-based management to a treat-to-target paradigm, detailing important treatment aims and reviewing the mechanisms of action of avai...
18 Aug 202115min
Efficacy and Safety of Anti-interleukin (IL) 23 and Janus Kinase (JAK) Inhibitors with Drs. William J. Sandborn and Jessica R. Allegretti
In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.
16 Mar 202116min
